Mankind Pharma jumps as Q2 PAT rises 37.7% YoY

Mankind Pharma jumped 8.45% to Rs 2,496.60 after the company reported strong financial results for Q2 FY27, with revenue, EBITDA and net profit increasing year on year.

The company's profit after tax rose 37.7% year on year to Rs 716 crore from Rs 520 crore. Sequentially, net profit increased 24.7% from Rs 574 crore in Q1 FY27.

Revenue from operations increased 17.3% year on year to Rs 4,338 crore from Rs 3,697 crore. On a quarter-on-quarter basis, revenue grew 7.6% from Rs 4,031 crore.

Gross profit increased 18.9% year on year to Rs 3,134 crore from Rs 2,635 crore. Gross margin improved 90 basis points to 72.2% from 71.3% a year earlier, although it declined 60 basis points from 72.8% in the previous quarter.

EBITDA rose 27.2% year on year to Rs 1,175 crore from Rs 924 crore. The EBITDA margin expanded 210 basis points to 27.1% from 25% in Q2 FY26. Sequentially, EBITDA increased 10.8% from Rs 1,060 crore, while the margin improved 80 basis points from 26.3%.

Domestic business revenue increased 14.8% year on year to Rs 3,657 crore, accounting for 84% of total revenue. Exports revenue surged 32.7% year on year to Rs 681 crore, accounting for 16% of total revenue.

The company said domestic growth was supported by 1.2 times volume outperformance against the Indian pharmaceutical market. Its chronic business recorded mid-teen growth, led by 19% growth in cardiac products and 16% in diabetes. Acute therapies grew 1.1 times the market, supported by 19% growth in gastroenterology and 26% in vitamins, minerals and nutrition products. The international business grew 33%, while over-the-counter products recorded muted growth during the quarter.

Mankind Pharma also said its acquisition of Armed Cell Therapeutics marked its entry into next-generation CAR-T therapies and strengthened its research and development capabilities.

Mankind Pharma operates in the pharmaceutical formulations and consumer healthcare sectors, with a portfolio spanning acute and chronic therapies, women's health and over-the-counter products. The company has 32 manufacturing facilities and seven research and development centres supported by more than 740 scientists. Its distribution network includes over 18,500 field professionals and reaches more than five lakh doctors across urban and rural India.

Powered by Capital Market - Live News